Mike O’Shaughnessy Joins CaamTech as General Counsel and Director of Intellectual Property

O’Shaughnessy brings decades of experience in intellectual property strategy, collaborations, and development within the life sciences and pharmaceutical industries

Michael (Mike) O’Shaughnessy has joined CaaMTech as the company’s Director of Intellectual Property. O’Shaughnessy joins CaaMTech with more than two decades of experience in the life sciences and pharmaceutical industries, and expertise in the licensing of intellectual property.  As the company’s Director of Intellectual Property, Mike will manage CaaMTech’s vast intellectual property portfolio, with over two hundred pending patent applications and issued patents protecting CaaMTech’s unmatched library of novel compounds and formulations.

Mike has served as an attorney and advisor to businesses in the life sciences and pharmaceutical industries for over 20 years, including Wyeth, Novartis, AbbVie, and Amgen.  He negotiated high-value asset sales, acquisitions, and licenses, and litigated complex intellectual property disputes throughout the U.S. District Courts, International Trade Commission, and the Federal Circuit as a partner at some of the world’s top law firms including Baker Botts, McDermott Will & Emery, and Finnegan.  Mike has extensive experience developing strategic partnerships and collaborations, managing and enforcing intellectual property portfolios, and navigating federal regulatory pathways.

“Mike brings exactly the expertise that we need right now,” said CaaMTech CEO, Andrew Chadeayne. “After six years of mostly internal development, I am eager to expand our capabilities through collaborations.”

As CaaMTech’s Director of Intellectual Property, O’Shaughnessy will manage the psychedelic industry’s foundational intellectual property portfolio.  CaaMTech’s unique focus on fundamental science has resulted in multiple pioneering innovations that support numerous areas of commercial development.  In managing CaaMTech’s IP department, O’Shaughnessy will focus on advancing the company’s technology towards commercial development through strategic partnerships and collaborations.

“I have been extremely fortunate to have worked with some of the best professionals throughout the pharmaceutical world.  I have helped clients develop innovative portfolios, and commercialize successful products that benefit millions of patients around the world.” said Mike O’Shaughnessy, CaaMTech’s newly appointed Director of Intellectual Property.  “But nothing has been as exciting as this opportunity to join such a talented and innovative team at CaaMTech, where we will truly break new ground together, and serve patients in desperate need for new and effective technologies.  We look forward to collaborating with partners throughout the industry to change the foundation of care.”